Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer
Status:
Completed
Trial end date:
2009-01-07
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of
rIL-21 and Caelyx in cancer patients who have relapsed after, or have persistent disease
after, first line therapy. Patients will be treated for 6 months.